Put companies on watchlist
SYNLAB AG
ISIN: DE000A2TSL71
WKN: A2TSL7
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

SYNLAB AG · ISIN: DE000A2TSL71 · EQS - Company News (77 News)
Country: Germany · Primary market: Germany · EQS NID: 1667183
28 June 2023 07:30AM

SYNLAB AG: SYNLAB invests in innovative Healthcare Centre in Florence


EQS-News: SYNLAB AG / Key word(s): Expansion
SYNLAB AG: SYNLAB invests in innovative Healthcare Centre in Florence

28.06.2023 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


SYNLAB invests in innovative Healthcare Centre in Florence, strengthening its position as leading diagnostic services provider in Italy

 

  • SYNLAB invests €8 million to build a new 4000m2 medical care centre within Florence’s Manifattura Tabacchi
  • The new centre will offer a wide range of routine diagnostics, specialty testing, and medical healthcare services for over 200,000 patients annually
  • This enables SYNLAB to continue its growth and support its strategy for future-proof healthcare systems

 

SYNLAB (FSE: SYAB), Europe’s leading provider of medical diagnostic services and specialty testing, is investing €8 million to build a new medical care centre within Florence’s Manifattura Tabacchi, an urban hub for science, businesses, and culture. The new, approximately 4000m2 medical care centre will feature state-of-the-art diagnostic equipment and has the capacity to serve up to 200,000 patients annually. Yesterday, SYNLAB together with several representatives from politics and business laid the cornerstone for the new centre in Florence.

“Integrating our medical services into the patient journey is a priority. With the new medical care centre, we foster and promote access to our expertise in specialty testing. At the same time, we utilise the professional and operational benefit of high-end diagnostic equipment. This way, we strategically expand our diagnostics and healthcare platform in Florence while creating a service portfolio that is key for future proof healthcare in Italy,” emphasises SYNLAB Group CEO Mathieu Floreani.

Andrea Buratti, CEO of SYNLAB Italy, further explains: “The new medical care centre will serve as a comprehensive “health hub”, providing regional access to a wide range of medical services. Amongst others, the centre offers blood collection, routine and specialty testing, as well as advanced diagnostic imaging, including high-field magnetic resonance imaging, CT scans, and mammography. What we are specifically proud of, the centre will feature the first women's health and prevention area of its kind in Tuscany.

SYNLAB’s new medical care centre will further emphasise easy accessibility and patient well-being. It will provide a safe and welcoming environment that meets ASHRAE standards and achieves LEED® Platinum certification for environmental sustainability. Furthermore, it promotes sustainable transportation options, including electrical vehicle charging points and proximity to public transport.

 

For more information:

 

Media contact:
David Rollik, FTI Consulting
david.rollik@fticonsulting.com
+49 30 288744 250
Investor contact:
Dr Anna Niedl, SYNLAB
anna.niedl@synlab.com
+49 160 9176 0464

 

About SYNLAB

  • SYNLAB Group (FSE: SYAB; ISIN: DE000A2TSL71) is the leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments and corporates.
  • Providing the leading level of service within the industry, SYNLAB is the partner of choice for routine and specialty diagnostics in human medicine. The Group continuously innovates medical diagnostic services for the benefit of patients and customers.
  • SYNLAB operates in 35 countries across four continents and holds leading positions in most markets, regularly reinforcing the strength of its network through a proven acquisition strategy.  More than 28,000 employees, including over 2,000 medical experts, contribute every day to the Group’s worldwide success.
  • SYNLAB performed around 600 million laboratory tests and achieved revenues of €3.25 billion in 2022.
  • More information can be found on www.synlab.com

 

***

 

Forward looking statements

This document does not constitute or form a part of, and should not be construed as, an offer for sale or subscription of or solicitation of any offer to purchase or subscribe for any securities in any jurisdiction.

Statements made in this document may include forward-looking statements. Forward-looking statements include all statements that are not historical facts and can be identified by the use of forward-looking terminology such as the words "believes", "expects”, “expected”, "may", "will", "would", "should", "seeks", "pro forma", "anticipates", "intends", "plans", "estimates", “estimated”, or the negative of any thereof or other variations thereof or comparable terminology, or by discussions of strategy or intentions. These statements are not guarantees of future actions or performance and involve risks, uncertainties and assumptions as to future events that may not prove to be accurate. Actual actions or results may differ materially from what is expressed or forecasted in these forward-looking statements. As a result, these statements speak only as of the date they were made and SYNLAB undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. It should be noted that past performance is not a guide to future performance. Interim results are not necessarily indicative of full-year results.

 



28.06.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SYNLAB AG
Moosacher Straße 88
80809 Munich
Germany
Phone: +49 1701183753
E-mail: ir@synlab.com
Internet: www.synlab.com/
ISIN: DE000A2TSL71
WKN: A2TSL7
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1667183

 
End of News EQS News Service

1667183  28.06.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1667183&application_name=news&site_id=boersengefluester_html
Visual performance / price development - SYNLAB AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.